(-0.46%) 5 048.42 points
(-0.98%) 38 086 points
(-0.64%) 15 612 points
(0.31%) $83.83
(-4.58%) $1.563
(0.12%) $2 345.20
(0.24%) $27.42
(0.90%) $928.80
(0.09%) $0.933
(0.16%) $10.97
(0.07%) $0.800
(0.02%) $92.18
-0.19% ¥ 2 619.00
Live Chart Being Loaded With Signals
Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide...
Stats | |
---|---|
Today's Volume | 206 000 |
Average Volume | 1.30M |
Market Cap | 1 408.00B |
EPS | ¥0 ( 2024-02-06 ) |
Next earnings date | ( ¥28.50 ) 2024-05-07 |
Last Dividend | ¥27.00 ( 2023-06-29 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 24.32 |
ATR14 | ¥1.016 (0.04%) |
Volume Correlation
Kyowa Kirin Co., Ltd. Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Kyowa Kirin Co., Ltd. Correlation - Currency/Commodity
Kyowa Kirin Co., Ltd. Financials
Annual | 2023 |
Revenue: | ¥442.23B |
Gross Profit: | ¥320.62B (72.50 %) |
EPS: | ¥151.03 |
Q4 | 2023 |
Revenue: | ¥136.18B |
Gross Profit: | ¥99.17B (72.83 %) |
EPS: | ¥51.40 |
Q3 | 2023 |
Revenue: | ¥106.84B |
Gross Profit: | ¥76.92B (71.99 %) |
EPS: | ¥59.35 |
Q2 | 2023 |
Revenue: | ¥105.68B |
Gross Profit: | ¥77.58B (73.41 %) |
EPS: | ¥16.53 |
Financial Reports:
No articles found.
Kyowa Kirin Co., Ltd. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥0 (N/A) |
¥27.00 (N/A) |
¥0 (N/A) |
¥27.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥2.50 | 2000-03-28 |
Last Dividend | ¥27.00 | 2023-06-29 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 49 | -- |
Total Paid Out | ¥539.50 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.35 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.32 | |
Div. Directional Score | 9.55 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8057.T | Ex Dividend Knight | 2024-07-18 | Annually | 0 | 0.00% | |
7313.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6556.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
5911.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4577.T | Ex Dividend Knight | 2023-11-29 | Semi-Annually | 0 | 0.00% | |
3834.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3085.T | Ex Dividend Knight | 2023-06-29 | Semi-Annually | 0 | 0.00% | |
1951.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
9506.T | Ex Dividend Knight | 2023-09-28 | Annually | 0 | 0.00% | |
8393.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.184 | 1.500 | 6.33 | 9.49 | [0 - 0.5] |
returnOnAssetsTTM | 0.0791 | 1.200 | 7.36 | 8.83 | [0 - 0.3] |
returnOnEquityTTM | 0.101 | 1.500 | 9.99 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.358 | -1.000 | 6.42 | -6.42 | [0 - 1] |
currentRatioTTM | 4.59 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.93 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 3.03 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0232 | -1.500 | 9.61 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 535.43 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 214.94 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 153.83 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0285 | -1.500 | 9.89 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.742 | 1.000 | 0.962 | 0.962 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.230 | 1.000 | 7.40 | 7.40 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 4.84 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.431 | 0.800 | -0.460 | -0.368 | [0.5 - 2] |
Total Score | 12.77 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 17.52 | 1.000 | 8.33 | 0 | [1 - 100] |
returnOnEquityTTM | 0.101 | 2.50 | 9.99 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 153.83 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.12 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 214.94 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.358 | 1.500 | 6.42 | -6.42 | [0 - 1] |
pegRatioTTM | 0.429 | 1.500 | -0.474 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.261 | 1.000 | 5.97 | 0 | [0.1 - 0.5] |
Total Score | 6.32 |
Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators